Cercar
01/07/2024
Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis
Martínez-Martínez, L, Lacruz, AC, Querol, L, Cortés-Vicente, E, Pascual, E, Rojas-García, R, Reyes-Leiva, D, Alvaro, Y, Moltó, E, Ortiz, E, Gallardo, E, Juárez, C, Mariscal, A. Inter-laboratory comparison of routine autoantibody detection methods for autoimmune neuropathies and myasthenia gravis. JOURNAL OF NEUROLOGY. 2024; 271(7)DOI:10.1007/s00415-024-12317-0. PMID:38578496. IF:4.600(Q1/2D).
11/06/2024
Editorial: New perspectives in the treatment of myasthenia gravis
Cortés-Vicente, E, Schreiner, B, Saccà, F, Narayanaswami, P. Editorial: New perspectives in the treatment of myasthenia gravis. Frontiers in Neurology. 2024; 15DOI:10.3389/fneur.2024.1418631. PMID:38919972. IF:2.800(Q2/5D).
01/06/2024
Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy
Saccà, F, Salort-Campana, E, Jacob, S, Cortés-Vicente, E, Schneider-Gold, C. Refocusing generalized myasthenia gravis: Patient burden, disease profiles, and the role of evolving therapy. EUROPEAN JOURNAL OF NEUROLOGY. 2024; 31(6)DOI:10.1111/ene.16180. PMID:38117543. IF:3.900(Q1/3D).
01/05/2024
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial
Tawil, R, Wagner, KR, Hamel, J, Leung, DG, Statland, JM, Wang, LH, Genge, A, Sacconi, S, Lochmüller, H, Reyes-Leiva, D, Diaz-Manera, J, Alonso-Perez, J, Muelas, N, Vilchez, JJ, Pestronk, A, Gibson, S, Goyal, NA, Hayward, LJ, Johnson, N, LoRusso, S, Freimer, M, Shieh, PB, Subramony, SH, van Engelen, B, Kools, J, Leinhard, OD, Widholm, P, Morabito, C, Moxham, CM, Cadavid, D, Mellion, ML, Odueyungbo, A, Tracewell, WG, Accorsi, A, Ronco, L, Gould, RJ, Shoskes, J, Rojas, LA, Jiang, JG. Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial. LANCET NEUROLOGY. 2024; 23(5)DOI:10.1016/S1474-4422(24)00073-5. PMID:38631764. IF:45.500(Q1/1D).